CYTK Myqorzo: First-Ever Phase 3 Win in Non-Obstructive HCM

Cytokinetics presented full Phase 3 data for Myqorzo (aficamten) in non-obstructive hypertrophic cardiomyopathy at the ESC Congress, and the headline holds: it is the first positive Phase 3 result ever recorded in nHCM. The topline from May 5 already confirmed the drug met both co-primary endpoints; the ESC presentation added the specific numbers, published simultaneously in the New England Journal of Medicine. The stock closed at $77.90.

Aficamten is a cardiac myosin inhibitor, a drug that damps the overactive heart-muscle contraction that drives hypertrophic cardiomyopathy. Hypertrophic cardiomyopathy is the most common inherited heart condition, affecting an estimated 400,000 to 800,000 people in the US, and roughly one-third have the non-obstructive form where blood flow is not blocked but the muscle is still thickened and stiff.

In ACACIA-HCM, a trial of 516 patients, aficamten improved peak oxygen consumption by 2.2 mL/kg/min versus placebo while lifting the Kansas City Cardiomyopathy Questionnaire score by 8.3 points (p<0.001). NT-proBNP, a biomarker of heart strain, fell 59.2%. The pVO2 benefit was nearly identical in men and women, with women making up 42% of the trial, addressing a known gap in HCM research. More than four in ten aficamten patients improved at least one NYHA functional class versus 27.8% on placebo, and left-atrial mechanics improved, a signal of the diastolic relief these patients need.

The victory is notable because the class leader already failed here. Bristol Myers Squibb’s mavacamten (Camzyos) missed its nHCM trial, ODYSSEY-HCM, leaving aficamten alone in a population with no approved drug. In nHCM, symptom burden stems from diastolic dysfunction rather than outflow-tract obstruction, which is why the mechanism translated unevenly across the class.

The safety caveat is the same one that boxed the class. Left ventricular ejection fraction fell below 50% in 10.5% of aficamten-treated patients versus 0.8% on placebo, consistent with the boxed warning on Myqorzo’s obstructive-HCM label. Most of those patients stayed on the drug at the same or a lower dose.

Cytokinetics plans to file a supplemental NDA for nHCM in Q4 2026. That filing is separate from the already-accepted MAPLE-HCM sNDA for obstructive HCM, which carries a PDUFA date of November 14, 2026. If the nHCM filing lands on schedule, aficamten could become the first drug cleared to treat both forms of HCM, a franchise expansion that would widen Myqorzo’s addressable market well beyond its current obstructive-only label. The near-term test is whether the FDA accepts the nHCM filing without asking for more data, given the ejection-fraction signal. The cardiometabolic catalysts worth tracking this year.

What It Means for the Trade

The ACACIA-HCM presentation converts a May topline into a publishable, congress-grade dataset, and the full numbers hold up the commercial thesis: a 2.2 mL/kg/min pVO2 gain (p<0.001), an 8.3-point KCCQ improvement, a 59.2% NT-proBNP reduction, and 42%-plus of patients improving at least one NYHA class versus 27.8% on placebo. This is the first-ever positive Phase 3 in non-obstructive HCM — BMS’s mavacamten missed ODYSSEY-HCM in the same setting — which gives Cytokinetics a monopoly position in a population of roughly 130,000 to 270,000 Americans with no approved therapy. The competitive significance is that aficamten is now demonstrably the broader-spectrum agent in the class: Myqorzo works where Camzyos failed, and the “first drug for both forms of HCM” label, if granted, is a differentiation claim that compounds through every guideline update and payer coverage policy.

The mechanics of why aficamten succeeded where mavacamten missed deserve scrutiny because they shape the FDA review. In nHCM, the pathology is diastolic — stiff, thickened muscle that can’t relax and fill, without outflow-tract blockade to measure acutely. A trial in this setting lives or dies on exercise-capacity endpoints (pVO2), which are noisy and placebo-fickle; ACACIA’s clean win on both co-primary endpoints with a sex-balanced population (42% women, with near-identical benefit in men and women) is the statistical quality that gets filings accepted without advisory drama. The left-atrial mechanics improvement is the mechanistic confirmation — the drug is producing the diastolic relief this population actually needs.

Mechanism and Competitive Context

The class context frames the stakes. Cardiac myosin inhibitors reduce the excessive actin-myosin cross-bridging that drives hypercontractility in HCM; both aficamten and mavacamten share the mechanism, but the nHCM divergence shows the molecules are not interchangeable — dosing properties, titration requirements, and pharmacokinetic differences separate them where the disease biology is subtle. Camzyos’s known liabilities — CYP2C19 interactions, a slow titration to steady state, and the ejection-fraction monitoring REMS-like framework — compare against aficamten’s faster onset and cleaner interaction profile, and in a chronic cardiology market managed largely by general cardiologists, the lower-burden agent tends to win the prescribing base.

The ejection-fraction signal is the label’s known cost: LVEF below 50% in 10.5% of aficamten patients versus 0.8% on placebo, consistent with the class’s boxed warning. Most patients stayed on therapy at same or reduced dose, which supports the manageability argument — but the FDA’s review of the nHCM filing will weigh exactly this, because nHCM patients may be on the drug for decades and an asymptomatic LVEF dip is the class’s long-tail safety question.

Risks and What Could Go Wrong

1. The FDA balks at the Q4 nHCM filing on the LVEF signal — an information request or a requirement for longer follow-up delays the label that the market is starting to price.
2. The November 14 MAPLE-HCM PDUFA (obstructive) lands with restrictive label language that colors the nHCM review before it even starts — the two decisions are procedurally separate but read together.
3. Camzyos’s entrenched obstructive franchise and BMS’s commercial scale mean the nHCM launch competes for cardiologist attention against a rival with years of guideline presence, even without an nHCM label.
4. Payer economics: a chronic-therapy label in a population managed on symptom-based criteria will face step-therapy and echocardiography-authorization friction that slows the ramp regardless of clinical logic.

Position read: CYTK at $77.90 is carrying a two-PDUFA second half (November 14 MAPLE, Q4 ACACIA filing) with the first-ever nHCM win banked — the franchise case is the strongest it has been. The November MAPLE decision is the next gate; size for it, and let the nHCM filing acceptance be the follow-on catalyst.

Source: Cytokinetics press release